News, press releases and the press kit.
Journalists: a person answers. Facts are checked against the registrations and the published studies before we say them.
Earlier releases, from 2018 to 2023, are available on request from the press contact.
Recognised for the design and for the outcome.
TIME Best Inventions2022 and 2024
Validation InstituteHealth outcomes validation, 2024
CES Innovation AwardsFifteen awards over four years, Digital Health
iF Design Award2023, 2024 and 2026
Red DotDesign Award 2024
Deloitte Technology Fast 50Canada, 2025
Health Value Awards2025
UpLink, World Economic ForumInnovator, healthy ageingAlso: McKnight’s Tech Awards Gold 2024; Fast Company Next Big Things in Tech 2023; the WHO Compendium of innovative health technologies for low-resource settings, 2024.
Boilerplate, logos and approved images.
Xandar Kardian Inc. is a medical technology company founded in 2017 and headquartered in Toronto, with research, development and manufacturing in Seoul and an office in New York. Its XK300 radar sensor measures heart rate and breathing rate through the air, from the wall or ceiling, with nothing worn, and is FDA-cleared (510(k) K202464, 2021) and registered in Canada, Australia, Singapore and Thailand. The XK300 is used on hospital wards, in long-term care, in home health and remote patient monitoring, and in correctional and behavioural health; more than 49,000 people have been monitored to date. Kardian, the company’s consumer line, brings the same radar science to the home. Xandar Kardian is privately held.
- Founded 2017. Delaware corporation, headquartered in Toronto.
- FDA 510(k) K202464, April 2021. Class II, prescription.
- ISO 13485 under MDSAP, certificate 0187405.
- 37 journal publications; 36 patents.
- Outcome validation: Validation Institute, 2024, 75.6% of hospital transfers, 201 patients.
- Sam Yang, Chief Executive Officer and Co-Founder.






Images may be used in editorial coverage of Xandar Kardian with credit. For anything else, please ask.